varicella zoster virus vaccine

The varicella-zoster virus (VZV) vaccine is a live attenuated biologic derived from the Oka strain, designed to elicit protective immunity against both varicella (chickenpox) and its reactivation, herpes zoster (shingles). This specific application involves a Phase 4 clinical trial conducted by The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT) to evaluate the vaccine's safety, immunogenicity, and efficacy in HIV-infected children. The study utilizes a two-dose regimen administered subcutaneously to children with stable immune status, defined by specific CD4 T lymphocyte thresholds. While the vaccine itself is an established product, this research focuses on optimizing immunization strategies for immunocompromised pediatric populations who are at higher risk for severe VZV-related complications.

Other names

VZV vaccinevaricella-zoster virus vaccinelive attenuated varicella vaccine